Cargando…
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
BACKGROUND & AIMS: Elimination of chronic HBV/HDV infection remains a major global health challenge. Targeting excessive hepatitis B surface antigen (HBsAg) release may provide an interesting window of opportunity to break immune tolerance and to achieve a functional cure using additional antivi...
Autores principales: | Burm, Rani, Van Houtte, Freya, Verhoye, Lieven, Mesalam, Ahmed Atef, Ciesek, Sandra, Roingeard, Philippe, Wedemeyer, Heiner, Leroux-Roels, Geert, Meuleman, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898450/ https://www.ncbi.nlm.nih.gov/pubmed/36748051 http://dx.doi.org/10.1016/j.jhepr.2022.100646 |
Ejemplares similares
-
HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection
por: Bazinet, Michel, et al.
Publicado: (2022) -
HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets
por: Colagrossi, Luna, et al.
Publicado: (2018) -
A Study of HDV in HBsAg Positive Patients in Tabriz, Northwestern Iran
por: Seifi, Sirus Jedary, et al.
Publicado: (2010) -
Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012) -
Seroprevalence of anti-HDV Ab and socioepidemiological characteristics among HBsAg-positive blood donors in Charmahal-o-Bakhtiyari province, Iran: Anti-HDV among HBsAg-positive blood donors
por: Tajbakhsh, Elahe, et al.
Publicado: (2011)